ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
About the study
This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
* Documented diagnosis of AHP, per physician's determination
EXCLUSION CRITERIA
Exclusion Criteria:
* Currently enrolled in a clinical trial for any investigational agent
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study Details
Contition
Acute Hepatic Porphyria
Age
12+
Participants Needed
150
Est. Completion Date
Apr 1, 2027
Treatment Type
OBSERVATIONAL
Sponsor
Alnylam Pharmaceuticals
ClinicalTrials.gov NCT Identifier
NCT04883905
Study Number
ALN-AS1-006
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?